Susumu Hijioka, MD, PhD, discusses the efficacy of first-line everolimus plus lanreotide in patients with unresectable or recurrent GEP-NETs.
Susumu Hijioka, MD, PhD
Advertisement
Susumu Hijioka, MD, PhD, works in the Department of Hepatobiliary and Pancreatic Oncology at National Cancer Center, in Japan.
Articles by Susumu Hijioka, MD, PhD
Advertisement
Latest Updated Articles
Dr Hijoka on Updated Efficacy Data With Everolimus Plus Lanreotide in GEP-NETsPublished: February 18th 2025 | Updated:
Advertisement
Advertisement
Trending on OncLive
1
FDA Accepts BLA for Ivonescimab Plus Chemotherapy in EGFR-Mutant NSCLC After TKI Progression
2
FDA Approval Sought for Lirafugratinib in Second-Line, FGFR2-Altered Cholangiocarcinoma
3
Aligning Patient Goals and Toxicity Burden Are Key in First-Line Chemo Selection in Pancreatic Cancer
4
Novel Targeted Agents Are Poised to Influence the MPN Treatment Paradigm: With John O. Mascarenhas, MD
5